Dr. Caroline Fichtner

Principal / Authorized Signatory

Dr. Caroline Fichtner

Principal / Authorized Signatory

Along with her experience in VC, biophysicist Dr Caroline Fichtner also spent many years working at the Max Planck Institute for Bioinorganic Chemistry in Mülheim an der Ruhr. At HTGF, the authorized signatory is responsible for the financing and development of technology start-ups in the life sciences field.


+49 – (0)228 – 82300 – 113


Posts & mentions

3. May 2022

Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

MUNICH, GERMANY, May 3, 2022 – Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+. All existing investors also participated in the round, including Bayern Kapital (with Wachstumsfonds Bayern 2), BioMedPartners, coparion, High-Tech Gründerfonds (HTGF), OCCIDENT and Seventure Partners. The new capital will be used to advance Tubulis’ proprietary pipeline of
5. October 2021

Life Science Pitch Day: Real entrepreneurs, real innovation, real added value

It was a special moment when CureVac founder Ingmar Hoerr shared his business story at the Life Science Pitch Day. More than 30 start-ups, investors, and scientists took part in the event at the end of September, which was organised by High-Tech Gründerfonds (HTGF) together with partners Bayer, Boehringer Ingelheim and the Innovation and Start-Up Center Biotechnology (IZB). We spoke to the event organisers at HTGF: Dr. Caroline Fichtner and Dr. Martin Pfister, both HTGF Principals, touched
1. June 2021

Medtech startup Inovedis closes 7-digit seed financing round

The medical technology start-up Inovedis located in Albstadt has closed a financing round of EUR 1.8 million, led by High-Tech Gründerfonds. The fund invests together with MBG Mittelständische Beteiligungsgesellschaft Baden-Württemberg and Volksbank Albstadt ChancenKapital and a group of renowned angel investors. Inovedis is developing a new surgical technique for shoulder injuries based on a PEEK implant. The optimal treatment result is achieved through simple, fast and safe surgical tec
11. December 2020

Resolve Biosciences Launches New Era in Single-Cell Spatial Analysis

Company announces $24 million Series A financing and appoints Jason T. Gammack as CEO to accelerate development and commercialization of Molecular Cartography™ platform Resolve Biosciences, the pioneer in Molecular Cartography™, announced the completion of a $24 million Series A financing round and the appointment of Co-founder Jason T. Gammack as Chief Executive Officer. The company's Molecular Cartography platform is a groundbreaking multi-analyte and highly multiplex spatial ana


6. October 2022
7th Life Science Pitch Day
In cooperation with Bayer, Boehringer Ingelheim and MEDICE, High-Tech Gründerfonds and the IZB are organizing the 7th LIFE SCIENCE PITCH DAY! Take your opportunity and present your technology in front of an exclusive audience of investors and CVCs! The Life Science Pitch Day is finally back. Once again, we would like to welcome you to our yearly event which will take place on the 6th October, 2022 in Munich.You will get the opportunity to listen to interesting keynotes from relevant industry p